This is accompanied by a reduction of recruited inflammatory cells into the TME and expression of tumour-promoting cytokines such as IL-6 and an improved response to anti-programmed death receptor-1 (PD-1) treatment45. The gene discussed is IL6; the disease is neoplasm.